Acquisition Details

QMS Medical Allied Services Ltd (QMS MAS) has completed the 100% acquisition of Saarathi Healthcare Pvt Ltd, making it a wholly owned subsidiary. The acquisition was completed through a phased approach:

  • June 2024: Initial acquisition of 51% stake
  • October 2025: Stake increased to 76%
  • September 2026: Acquired remaining 24% stake for complete ownership

Transaction Terms

The company acquired the balance 24% equity stake comprising 1,98,000 shares for a cash consideration of ₹14.225 crore, increasing its shareholding in Saarathi Healthcare from 76% to 100%.

Strategic Rationale

The acquisition marks an important step in QMS MAS's strategy to build an integrated healthcare services platform spanning:

  • Patient screening
  • Early diagnosis
  • Disease management
  • Patient engagement

Complementary Capabilities

QMS MAS Specializations:

  • Patient screening services through innovative Patient Service Programs (PSP)
  • Supply of diagnostic medical devices
  • Advanced diagnostic testing access
  • Early intervention and preventive healthcare

Saarathi Healthcare Capabilities:

  • Disease management
  • Early diagnosis and screening through point-of-care devices
  • Disease awareness and access programmes across therapies
  • Digital tools combined with physical patient engagement
  • Healthcare programmes across different stages of the patient journey

Management Commentary

Mr Mahesh Makhija, CMD, QMS Medical Allied Services Ltd, stated: "The 100% acquisition of Saarathi Healthcare marks an important milestone in our journey towards building a comprehensive and integrated healthcare services platform. By bringing together QMS MAS's strengths in patient screening and diagnostics with Saarathi's capabilities in disease management and patient engagement, we aim to provide a more connected continuum of care. Full ownership will enable us to drive deeper integration, strengthen operational synergies and create greater value for patients, healthcare partners and stakeholders."

Growth Context and Targets

The development comes amid a period of accelerated growth for QMS MAS:

  • June 2026: Company migrated to the NSE Mainboard
  • Recently entered into a five-year exclusive agreement with Germany-based HEINE Optotechnik for marketing and distribution of primary diagnostic instruments in India
  • Company has set an ambitious target of surpassing the ₹500 crore revenue milestone by FY29
  • Two key growth engines: Scalable product vertical and growing healthcare services portfolio

Company Business Overview

QMS Medical Allied Services Ltd operates as an integrated healthcare solutions company across healthcare products and services, providing capabilities spanning:

  • Patient engagement
  • Patient Service Programs (PSPs)
  • Disease management
  • Preventive healthcare initiatives
  • Patient screening and medical camps
  • Healthcare staffing
  • Medical and diagnostic solutions

The company supports pharmaceutical companies, healthcare providers, and patients by improving patient access, enabling continuity of care, and enhancing healthcare outcomes through healthcare expertise, digital capabilities, and scalable service models.